Prostate cancer
CTD - Clinical Trials Data
Abbreviations
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
© 2021 - 2025 | MedAgora Consulting srl